MedTrace Logo

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03836053 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-09-11

Study results available
· View outcomes & findings →

Summary

To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

AMG 420

28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2022-04-21
Completion
2022-04-21
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Japan
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03836053 on ClinicalTrials.gov